Wockhardt hit by FDA alert on Chikalthana plant

An `import alert' results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, the FDA website says.

November 28, 2013 / 09:40 IST

26 Aug, 2025 12:21

Volume

Todays L/H

The US Food and Drug Administration has imposed an "import alert", effectively a ban, on the Chikalthana plant operated by Indian generic drugmaker Wockhardt Ltd, the regulator said in a notice on its website, sending the company's shares down as much as 13.5 percent.

An "import alert" results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices, according to the FDA website.

A spokesman for Wockhardt was not available for comment.

The latest FDA action against Wockhardt comes amid a slew of regulatory rebukes this year. Its factory in Chikalthana in western India was last month hit by the British drug regulator's curb on imports from the plant over manufacturing deficiencies.

Indian firms, which make nearly 40 percent of generic and over-the-counter drugs for the US market, are facing more regulatory woes, including a record fine for Ranbaxy Laboratories, amid increased scrutiny by overseas regulators.

first published: Nov 27, 2013 10:55 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.